This study was designed to evaluate the in vivo activity of cytochrome P450 3A (CYP3A) in 49 healthy Japanese subjects aged 22-58 years using endogenous cortisol 6b-hydroxylation clearance [CLm(6b)], a novel biomarker for CYP3A phenotyping. CLm(6b) in the 49 healthy subjects was 2.40 6 0.79 ml/min with an approximately 4-fold interindividual variability of CYP3A activity. The mean clearance in the 24 women was 2.50 6 0.89 ml/min; the value in the women was higher than in the 25 men (2.30 6 0.69 ml/min) by approximately 9%. We also measured the change of CLm(6b) in 14 healthy subjects in the morning at 10:00-12:00 every 2 or 3 days over a period of 36-53 days and observed a 1.5-fold to 3.4-fold dayto-day intraindividual variability in the CYP3A activity. The mean value for CLm(6b) in each subject for 36-53 days was 2.54 6 0.76 ml/min (n = 14). We also evaluated the CLm(6b) every 2 hours from 8:00-20:00 in 26 healthy subjects. The within-day intraindividual clearance variability was 1.1-fold to 2.5-fold (2.45 6 0.91 ml/min, n = 26). No characteristic diurnal rhythms were observed in the in vivo activity of CYP3A.
Introduction
Cytochrome P450 3A (CYP3A) metabolizes a number of xenobiotics, including therapeutic drugs, environmental chemicals, and dietary components as well as endogenous substrates such as steroids and bile acids. CYP3A, the most abundant cytochrome P450 enzyme, is involved in the metabolism of approximately 50% of all drugs currently used in humans (Watkins, 1994; Wilkinson, 1996; Streetman et al., 2000) . Marked interindividual variabilities in the catalytic function to metabolize CYP3A substrates have been demonstrated, but genetic polymorphism of CYP3A cannot explain the variability in CYP3A-mediated metabolism. Therefore, CYP3A phenotyping or in vivo CYP3A activity evaluation have been suggested prospectively as an attractive approach to predict optimal dosage ranges for improving therapeutic outcomes and minimizing adverse effects (Zaigler et al., 2000; Dahl, 2002) .
We previously reported evidence for the validity of endogenous cortisol 6b-hydroxylation clearance [CLm(6b)] as a new index for in vivo CYP3A phenotyping in humans (Furuta et al., 2001 (Furuta et al., , 2003 . It is calculated using the amount of urinary excreted 6b-hydroxycortisol (6b-OHF) divided by the area under the plasma concentration-time curve (AUC) of cortisol (F). The inhibitory effects of clarithromycin on in vivo CYP3A activity have clearly been demonstrated by the CLm(6b) of endogenous cortisol, but not by the conventional index of urinary ratio 6b-OHF/F (Furuta et al., 2003) . The CLm(6b) can precisely assess in vivo CYP3A activity even when there are intraindividual or interindividual variations in the metabolic clearance of cortisol mediated by enzymes other than CYP3A, and in the renal clearance of cortisol. However, it is still unclear when and how the activity of CYP3A changes throughout the day, week, and month in humans.
In the present study, we investigated the intraindividual and interindividual variabilities of in vivo CYP3A activity in Japanese subjects, using endogenous cortisol CLm(6b). We examined CLm (6b) in 49 healthy subjects aged 22-58 years. The present study was also designed to evaluate the in vivo activity of CYP3A every 2 hours from 8:00-22:00 in 26 healthy adult subjects. Furthermore, we measured the change of CLm(6b) in 14 healthy subjects in the morning at 10:00-12:00 every 2 or 3 days over a period of 36 to 53 days. This is the safest, simplest phenotyping procedure to sequentially observe in vivo enzyme activity throughout the day, week, and month because no administration of a probe drug is required, thus also avoiding any potential physiologic changes resulting from the probe drug. 6b, 11b, 17a, 11b, were purchased from Steraloids (Wilton, NH). Cortisol was purchased from Sigma (St. Louis, MO). Stable isotopically labeled cortisol- [1,2,4,19-13 C 4 ]cortisol (cortisol-13 C 4 )-for use as an analytical internal standard was synthesized by our laboratory (Furuta et al., 2000b) . The isotopic compositions of the labeled cortisol were .97.3 atom %. All other chemicals and solvents were of analytic-reagent grade and were used without further purification. Study Subjects. The study was approved by the Tokyo University of Pharmacy and Life Sciences Human Subjects Review Board, and written informed consent was obtained from all participants. All subjects were Japanese and nonsmokers. No individuals were taking any medications or herbal supplements. All subjects abstained from alcohol and grapefruit juice for at least 4 weeks before and during the study period.
Materials and Methods

Chemicals
In study 1, CLm(6b) was measured in 49 healthy adult subjects (25 men and 24 women) aged 22-58 years (range: 28.3 6 8.8 years). In study 2, 26 healthy adult subjects (16 men and 10 women, numbered I-XXVI) aged 22 to 53 years (range: 28.8 6 8.7 years) were observed for partial diurnal variation of in vivo CYP3A activity. Blood samples (5-10 ml) were obtained every 30 minutes or 1 hour between 10:00 and 16:00, 8:00 and 22:00, 9:00 and 20:00, or 9:00 and 22:00. In study 3, 14 healthy adult subjects (2 men and 12 women, numbered 1-14) aged 23-58 years (range: 30.5 6 10.7 years) were observed for dayto-day variation of in vivo CYP3A activity. Blood samples (5-10 ml) were obtained at 10:00, 11:00, and 12:00 every morning, every second or third day for 36-53 days.
Heparinized blood was collected in glass tubes and centrifuged. Urine samples were obtained at timed periods of 2 hours, and the volume and pH of the urine samples were recorded. The plasma and urine samples were stored at 220°C until analysis. Plasma concentrations of cortisol were analyzed by gas chromatography-mass spectrometry using cortisol-13 C 4 as the internal standard (Furuta et al., 2000a) . Urinary excreted amounts of 6b-OHF were analyzed by high-performance liquid chromatography using 6a-hydroxycorticosterone as the internal standard (Furuta et al., 2004; Shibasaki et al., 2012) . Both the interassay and intra-assay coefficients of variation (CV) were ,1.80% for gas chromatography-mass spectrometry-selected ion monitoring, and both were ,2.5% for high-performance liquid chromatography.
6b-Hydroxylation Clearance of Endogenous Cortisol for Phenotyping In Vivo CYP3A Activity. Fractional metabolic clearance specific for CLm(6b) was used for phenotyping in vivo CYP3A activity. Because plasma concentrations of endogenously secreted cortisol (F) are considered steady state, the amount of the metabolite 6b-OHF produced from cortisol (F) in the body can be expressed as CLm(6b) Â AUC(F), where AUC(F) is the area under the concentration-time curve of cortisol. The metabolite is then excreted as an unconjugated form in urine. Therefore, the amount of urinary excreted 6b-hydroxycortisol (X(6b)) is expressed as CLm(6b) Â AUC(F). In the present study, the CLm(6b) (Eq. 1) was calculated as X(6b) during the 2-hour urine collection period divided by the corresponding 2-hour AUC(F) (Furuta et al., 1996 (Furuta et al., , 2001 (Furuta et al., , 2003 : Figure 1 shows the distribution of CLm(6b) in 49 healthy subjects (25 men and 24 women) aged 22-58 years (range: 28.3 6 8.8 years). The values were in the range of 1.23 and 4.75 ml/min with 3.9-fold interindividual variability of CYP3A activity. The mean clearance was 2.40 6 0.79 ml/min. The clearances in most subjects were in the range of 1.5-3.5 ml/min (Fig. 1) . The mean clearance for 24 female subjects was 2.50 6 0.89 ml/min and 2.30 6 0.69 ml/min for 25 male subjects.
Within-Day Variability of In Vivo CYP3A Activity (Study 2). Figure 2 shows the time courses of CLm(6b) every 2 hours from 8:00-22:00 in 26 healthy subjects (16 men and 10 women, numbered I-XXVI) aged 22-53 years (range: 28.8 6 8.7 years). Of 26 subjects (Table 1) , the highest value was 5.14 ml/min for subject XXV, and the lowest was 0.81 ml/min for subject XXI (Table 1 ). The mean values of CLm(6b) in each subject were 1.23-4.79 ml/min (n = 26, 2.45 6 0.91 ml/min) with 3.9-fold (= 4.79/1.23) interindividual variability of CYP3A activity (Table 1) . Within-day intraindividual variabilities were 1.1-to 2.5-fold (CV = 4.0%-34.2%) ( Table 1 ). There was no characteristic diurnal rhythm in CLm(6b) (Fig. 2) .
Day-to-Day Variability of In Vivo CYP3A Activity (Study 3). Figure 3 shows the time course of CLm(6b) once at 10:00-12:00 in the morning at least every 2 or 3 days over a period of 36-53 days in 14 healthy subjects (numbered 1-14) aged 23-58 years (range: 30.5 6 10.7 years). Of 14 subjects, the highest value was 5.85 ml/min for subject 13, and the lowest was 0.91 ml/min for subject 5 ( Table 2) . The mean values of CLm(6b) in each subject for 36-53 days were 1.76-4.17 ml/min (n = 14; 2.54 6 0.76 ml/min) with 2.4-fold (= 4.17/ 1.76) interindividual variability of CYP3A activity (Table 2) . Dayto-day intraindividual variabilities of CLm(6b) were 1.5-to 3.4-fold (CV = 11.2%-30.2%) ( Table 2 ).
DISCUSSION
As is well known, marked interindividual variabilities in the catalytic function of metabolizing CYP3A substrates have been demonstrated. However, genetic polymorphism in CYP3A cannot explain the variability in CYP3A-mediated metabolism. The physiologic changes through the day or over a longer period may affect the variability of in vivo enzyme activity within an individual and could potentially influence drug metabolism and pharmacokinetics. Recently, human chronokinetic studies have partly explained the chronopharmacodynamic phenomena (Bruguerolle, 1998) . The time of drug administration is a possible factor in the metabolic and pharmacokinetic variations, but systematic investigations of the variability of in vivo CYP3A activity in the same individuals throughout the day via administration of a probe drug such as midazolam, erythromycin, or omeprazole have been difficult. The urinary excretion ratio of 6b-hydroxycoritisol to cortisol (6b-OHF/F) has been used extensively as a noninvasive index for evaluating not only in vivo CYP3A activity in drug-drug interactions but also the statistical correlation of CYP3A activity with such genetic and/or environmental factors as disease and ethnic differences (Ged et al., 1989; Wilkinson, 1996; Monsarrat et al., 1998; PichardGarcia et al., 2000) . However, the correlations between morning spot and 24-hour urinary ratios have been mixed. Some results have shown the absence of any changes in the ratio of 6b-OHF/F in spot urine throughout the day (Galteau and Shamsa, 2003; Micuda et al., 2007) . Conversely one report indicated a diurnal rhythm, with increased levels in the evening (Ohno et al., 2000) . It should be noted that the urinary ratio 6b-OHF/F is valid as the index for in vivo CYP3A activity only when the renal clearance of cortisol is consistent (Furuta et al., 2001 (Furuta et al., , 2003 Peng et al., 2011) , because the urinary ratio 6b-OHF/F is a function of two independent parameters: metabolic clearance specific for 6b-hydroxylation and renal clearance of cortisol. By using a probe drug in phenotyping, the clearance of the drug should provide the best estimate of in vivo catalytic activity of the enzyme of interest. If the probe drug has multiple metabolic pathways, the fractional metabolic clearance corresponding to the pathway of interest should be an appropriate measure (Watkins, 1994) . In our previous study, we provided evidence for the validity of CLm(6b) as an appropriate index for phenotyping in vivo CYP3A activity by using stable isotope methodology (Furuta et al., 2001 (Furuta et al., , 2003 . The method can precisely assess in vivo CYP3A activity even when there are intraindividual and interindividual variations in the cortisol metabolic clearance mediated by enzymes other than CYP3A and in the renal clearance of cortisol. In this case, the clearance CLm(6b) can be estimated as the index for phenotyping in vivo CYP3A activity under the assumption that the metabolite 6b-hydroxycortisol does not undergo further metabolism (Furuta et al., 1996) . On the other hand, cortisol reversibly converts to cortisone by 11b-hydroxysteroid dehydrogenase (Draper and Stewart 2005) . Cortisone is then partly metabolized to 6b-hydroxycortisone by CYP3A, which may interconvert to 6b-hydroxycortisol by 11b-hydroxysteroid dehydrogenase in vivo. A recent study by Peng et al. (2011) , however, demonstrated that there was no significant difference in the magnitude of inhibition of CYP3A activity by itraconazole, estimated by either the formation clearance of 6b-hydroxycortisol from cortisol or the combined clearance of 6b-hydroxycortisol from cortisol and Fig. 3 . Time course of endogenous cortisol 6b-hydroxylation clearance [CLm(6b)] for phenotyping in vivo cytochrome P450 3A (CYP3A) activity in humans: day-to-day variability of in vivo CYP3A activity in subjects 1-14. Each value of CLm(6b) is represented at a midpoint time (11:00) in the 2-hour urine collection period (10:00-12:00). 6b-hydroxycortisone from cortisone, indicating that the formation clearance of 6b-hydroxycortisol should reflect the combined formation clearance of 6b-hydroxycortisol and 6b-hydroxycortisone. It seems reasonable to assume that there is a negligible contribution of 6b-hydroxycortisone to the formation clearance of 6b-hydroxycortisol in phenotyping in vivo CYP3A activity.
In the present study, we investigated the interindividual variabilities of in vivo CYP3A activity in 49 healthy subjects aged 22-58 years by use of CLm(6b). Furthermore, we observed the time course of CLm (6b) every 2 hours from 8:00-22:00 in 26 healthy subjects and once at 10:00-12:00 in the morning every 2 or 3 days over a period of 36-53 days in 14 healthy subjects to evaluate the within-day and day-to-day intraindividual variabilities of in vivo CYP3A activity.
The present study demonstrated less than 3.9-fold interindividual variabilities of CLm(6b) in studies 1-3. There were no statistically significant intraindividual variabilities in the values of CLm(6b) in the within-day (1.1-to 2.5-fold; CV = 4.0-34.2%) or day-to-day studies (1.5-to 3.4-fold; CV = 11.2-30.2%) (Tables 1 and 2 ). The mean value of CLm(6b) in 49 healthy subjects (study 1) was 2.40 6 0.79 ml/min (CV = 32.9%), which was consistent with the mean clearance values in 26 subjects obtained from the study 2 (within-day: 2.45 6 0.91 ml/min) and in 14 subjects from the study 3 (day-to-day: 2.54 6 0.76 ml/min). The intraindividual variability of in vivo CYP3A activity could be due to dietary, environmental, or hormonal factors. No characteristic within-day and day-to-day variations or rhythms were observed in CLm(6b), and the clearance in most subjects was in the range of 1.5-3.5 ml/min (Figs. 1-3) . Yin et al. (2004) reported that there was a large interindividual variability, with a 30-fold difference, and a small intraindividual variability (CV = 31.1%) in the urinary ratio 6b-OHF/F. This indicates that the urinary ratio 6b-OHF/F should be affected by wide interindividual variability in the renal clearance of cortisol (Furuta et al., 2001 (Furuta et al., , 2003 .
Our present study also demonstrated that the mean clearance in 24 women (2.50 6 0.89 ml/min) was higher than in the 25 men (2.30 6 0.69 ml/min) by approximately 9% (Fig. 1) , which is consistent with previous studies using CYP3A substrates or markers (Horsmans et al., 1992; Harris et al., 1995; Inagaki et al., 2002; Zhu et al., 2003; Cotreau et al., 2005; Lutz et al., 2010) ; however, we found no statistically significant sex-related difference (P = 0.37). The presence of the female sex steroids estrogen and progesterone in vivo may play a role in the modulation of this sex-related difference. The higher clearance rates of drugs in women could be a result of CYP3A transcriptional regulation by endogenous steroid hormones through the nuclear pregnane X receptor. Successive measurements of estrogen and progesterone in relation to CYP3A activity during the menstrual cycle would be of great interest, and should provide further insight into sex-based differences in drug metabolism and pharmacokinetics. This is the first report to demonstrate the interindividual and intraindividual (within-day and day-to-day) variabilities in in vivo CYP3A activity using CLm(6b). The results presented here should provide important, useful information for predicting individual drug metabolism and disposition in various patients or identifying individuals with important variants that affect CYP3A activity in humans.
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